ASCO 2021 Bladder Cancer

Viewing 1-20 of 38 articles

ASCO 2021: Optimizing Urothelial Cancer Management From Organ-Confined to Metastatic Disease: A Multidisciplinary Approach – Urologic Oncologist Perspective

ASCO 2021: Optimizing Urothelial Cancer Management From Organ-Confined to Metastatic Disease: A Multidisciplinary Approach – Radiation Oncologist Perspective

ASCO 2021: Optimizing Urothelial Cancer Management From Organ-Confined to Metastatic Disease: A Multidisciplinary Approach – Medical Oncologist Perspective

ASCO 2021: Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy As Bladder Sparing Treatment for Muscle-Invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial

ASCO 2021: Optimizing Urothelial Cancer Management from Organ-Confined to Metastatic Disease: A Multidisciplinary Approach

ASCO 2021: Phase 2 Trial of Gemcitabine, Cisplatin, plus Nivolumab with Selective Bladder Sparing in Patients with Muscle- Invasive Bladder Cancer (MIBC): HCRN GU 16-257

ASCO 2021: Conundrums in First-Line Urothelial Carcinoma: Are More Drugs Beyond Platinum Chemotherapy Always Better?

ASCO 2021: Inducible T-Cell Co-Stimulatory (ICOS) Receptor Agonist, Feladilimab (Fela), Alone and in Combination (Combo) with Pembrolizumab (P): Results from INDUCE-1 Urothelial Carcinoma (UC) Expansion Cohorts (ECs).

ASCO 2021: First-Line Pembrolizumab (Pembro) in Cisplatin-Ineligible Patients with Advanced Urothelial Cancer (UC): Response and Survival Results up to Five Years from the KEYNOTE-052 Phase 2 Study

ASCO 2021: Conundrums in First-Line Urothelial Carcinoma: Is More Always Better?

ASCO 2021: A Randomized Phase II Study Comparing Cisplatin and Gemcitabine with or Without Berzosertib in Patients with Advanced Urothelial Carcinoma

ASCO 2021: Inducible T-Cell Co-Stimulatory Receptor Agonist, Feladilimab, Alone and in Combination With Pembrolizumab: Results From INDUCE-1 Urothelial Carcinoma Expansion Cohorts

ASCO 2021: First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Advanced Urothelial Cancer: Response and Survival Results Up to Five Years From the KEYNOTE-052 Phase 2 Study

ASCO 2021: Steps Toward a Bladder-Intact Cure for Muscle-Invasive Bladder Cancer

ASCO 2021: Phase II Trial of Durvalumab Plus Tremelimumab With Concurrent Radiotherapy in Patients With Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach: IMMUNOPRESERVE-SOGUG Trial

ASCO 2021: Phase 2 Trial of Gemcitabine, Cisplatin, Plus Nivolumab With Selective Bladder Sparing in Patients With Muscle-Invasive Bladder Cancer: HCRN GU 16–257

ASCO 2021: Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy As Bladder Sparing Treatment for Muscle-Invasive Bladder Cancer: A Multicenter Phase 2 Trial

ASCO 2021: Effect of BCG Exposure on Severity of COVID-19 Infection: A COVID-19 and Cancer Consortium (CCC19) Study

ASCO 2021: Barriers to Best Care: A Patient's Perspective

ASCO 2021: Immunotherapy as Curative Therapy in Advanced Kidney and Bladder Cancer: Fantasy or Reality?

1
2